Amring Pharmaceuticals
Amring Pharmaceuticals Inc. is a US subsidiary of Nordic Pharma Group B.V. that commercializes pharmaceutical products and FDA-cleared medical devices, including the LACRIFILL canalicular occlusive device for dry eye disease, serving ophthalmology healthcare providers in the United States.
- Company typePrivate
- Founded2014
- HeadquartersBerwyn, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Amring Pharmaceuticals firmographics
Firmographics- Name
- Amring Pharmaceuticals
- Legal name
- Amring Pharmaceuticals Inc.
- Website
- https://amringusa.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Amring Pharmaceuticals Inc. is a US subsidiary of Nordic Pharma Group B.V. that commercializes pharmaceutical products and FDA-cleared medical devices, including the LACRIFILL canalicular occlusive device for dry eye disease, serving ophthalmology healthcare providers in the United States.
- Ownership category
- akta.pro rank
Amring Pharmaceuticals industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
- akta.pro secondary industries
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Amring Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Berwyn
- HQ country
- United States
- HQ region
- North America
Markets served
Amring Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D
Revenue model
- Pharmaceutical and Medical Device Sales: Amring Pharmaceuticals generates revenue through the sale of pharmaceutical products and medical devices, including the novel dry eye disease therapy acquired through the Visant Medical acquisition.
Go-to-market motion1 record
Amring Pharmaceuticals product offering
Product offeringCore offering
Amring Pharmaceuticals is a privately-held niche generic pharmaceutical company that develops, manufactures, and commercializes pharmaceutical products and FDA-cleared medical devices. Operating as the US subsidiary of Nordic Pharma Group B.V., the company focuses on the ophthalmology sector following its acquisitions of Visant Medical (LACRIFILL canalicular occlusive device for dry eye treatment) and Laminar Inc.
Differentiator
Problem solved
Functional benefit
Products and services
- LACRIFILL Canalicular Occlusive Device FDA-cleared canalicular occlusive medical device designed for dry eye disease treatment, commercialized through Amring Pharmaceuticals' US healthcare provider channel targeting ophthalmologists and eye care professionals.
Companies that use Amring Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Amring Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Amring Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Nordic Pharma Group B.V.coreNordic Pharma Group B.V. is the parent company of Amring Pharmaceuticals Inc. Amring operates as a subsidiary conducting US operations, including the acquisition and launch of novel therapies such as the dry eye disease treatment from Visant Medical.
- Visant Medical, Inc.coreNordic Pharma Group B.V., through its subsidiary Amring Pharmaceuticals Inc., completed the acquisition of Visant Medical, Inc. in December 2023. The acquisition included the FDA-cleared LACRIFILL canalicular occlusive device for dry eye treatment, which Amring plans to launch in the United States.
- Laminar Inc.minorAmring Pharmaceuticals Inc. acquired Laminar Inc. in November 2023 for an undisclosed sum. This acquisition was part of Nordic Pharma's expansion strategy in the pharmaceutical sector.
Scale indicators1 record
Amring Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Nicox: Ophthalmology company developing and commercializing treatments for ocular surface diseases including dry eye. Comparable as a specialty ophthalmology player focused on the same therapeutic area Amring targets.
- Kala Bio: Specialty ophthalmology company that commercialized EYSUVIS, an FDA-approved dry eye therapy. Comparable as a small-cap, focused dry eye treatment company selling through ophthalmology channels.
- Ocular Therapeutix: Specialty ophthalmology biopharmaceutical company developing therapeutics for dry eye disease and other ocular surface conditions using novel drug delivery approaches. Directly comparable as a focused ophthalmology player pursuing differentiated dry eye therapies.
Emerging players
- Sun Pharmaceutical Industries: India-headquartered global generic and specialty pharmaceutical company with US operations including ophthalmic generics. Comparable to Amring's positioning as a niche US-focused generic/specialty pharma player.
- Aerie Pharmaceuticals (Alcon): Ophthalmology specialty pharmaceutical company focused on glaucoma, dry eye, and other eye diseases, now part of Alcon. Comparable as a specialty ophthalmology pharma player with overlapping therapeutic focus.
- Lupin Pharmaceuticals: India-based generic pharmaceutical company with US operations and a portfolio that includes niche specialty and ophthalmic generics. Comparable to Amring's generic pharma heritage and US specialty pharma positioning.
Broad incumbents
- Allergan (AbbVie): Owner of Restasis, the leading prescription dry eye pharmaceutical, and a broad ophthalmology portfolio. Comparable as a large incumbent competing in the same dry eye treatment market that Amring is entering with LACRIFILL.
- Bausch + Lomb: Large established ophthalmology company with a broad portfolio spanning pharmaceuticals, surgical devices, and consumer eye care including dry eye products. Highly comparable as a specialty ophthalmology incumbent competing in the same dry eye and ophthalmic device categories Amring is targeting.
- Teva Pharmaceutical Industries: Large generic and specialty pharmaceutical company with significant US operations and a portfolio that has included ophthalmology products. Comparable to Amring as a private/generic specialty pharma operating in the US market.
- Alcon: Global leader in eye care with pharmaceutical and surgical/device franchises, including treatments and devices for dry eye and ocular surface disease. Directly comparable as a broad incumbent serving ophthalmologists with overlapping therapeutic and device offerings.
Market position
Customer concentration
Amring Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Amring Pharmaceuticals leadership team
Management profileNumber of profiles
Amring Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries2 records
Amring Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Amring Pharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Amring Pharmaceuticals
What does Amring Pharmaceuticals do?
Amring Pharmaceuticals is a privately-held niche generic pharmaceutical company that develops, manufactures, and commercializes pharmaceutical products and FDA-cleared medical devices. Operating as the US subsidiary of Nordic Pharma Group B.V., the company focuses on the ophthalmology sector following its acquisitions of Visant Medical (LACRIFILL canalicular occlusive device for dry eye treatment) and Laminar Inc.
Is Amring Pharmaceuticals a public or private company?
Amring Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was Amring Pharmaceuticals founded?
Amring Pharmaceuticals was founded in 2014. It employs 11 to 50 people.
Where is Amring Pharmaceuticals based?
Amring Pharmaceuticals is headquartered in Berwyn, United States, in the North America region.
How does Amring Pharmaceuticals make money?
One revenue line is on record: pharmaceutical and Medical Device Sales.
Who are Amring Pharmaceuticals's main competitors?
Direct peers on record are Nicox, Kala Bio and Ocular Therapeutix. Emerging players are Sun Pharmaceutical Industries, Aerie Pharmaceuticals (Alcon) and Lupin Pharmaceuticals. Broad incumbents are Allergan (AbbVie), Bausch + Lomb, Teva Pharmaceutical Industries and Alcon.
Does Amring Pharmaceuticals have an API?
No public API is recorded for Amring Pharmaceuticals.
What industry is Amring Pharmaceuticals in?
Amring Pharmaceuticals's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.